dexamethasone,lenalidomide,carfilzomib
amgen
['mmsm', 'atlas']
next, the atlas trial of extended post-asct krd vs r maint. median pfs 59 months in krd vs 41 months in r. higher mrd negativity at c6 for krd. no os diff. median pfs not reached in those who deescalated krd --&gt; r when mrd-neg at c6. #mmsm #asco22 
Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????